ASPIRE Reduction-to-Practice (Seed)
Supports translational chemistry and automation platform development through university-linked partnerships.
ASPIRE — A Specialized Platform for Innovative Research Exploration — is a National Center for Advancing Translational Sciences (NCATS) research program designed to transform chemistry from an individualized craft into a modern, information-based science. The program addresses fundamental challenges of standardization, reproducibility, and predictability in how chemical compounds behave in biologi…
Modernization of chemical research through lab automation, microfluidic flow chemistry, high-throughput screening, and machine learning applied to biological systems.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see the timeline
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Submit & reportSAM.gov Registration and UEI Guide for Federal Grant Applicants
Learn how SAM.gov registration, UEI numbers, Grants.gov accounts, organization profiles, workspace roles, and renewal timing fit together.
More from NCATS
All grants from this funder →Oligonucleotide Toxicity (OligoTox) Open Data Challenge
🇺🇸NCATS · United States
Pays cash prizes for public datasets that help predict oligonucleotide drug toxicity in human cells.
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NCATS STTR Phase II
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to continue and expand translational R&D begun in STTR Phase I toward a commercial product.
NCATS SBIR Phase I
🇺🇸NCATS · United States
Supports small businesses testing translational science tools and technologies through early feasibility and commercialization groundwork.
NCATS SBIR Phase II
🇺🇸NCATS · United States
Backs small businesses scaling proven translational findings into applied solutions and early market readiness.
Similar grants
Browse the directory →
NIH Common Fund Venture Program — Open Funding (Seed)
🇺🇸NIH Common Fund · United States
Supports high-potential short- to medium-range initiatives that can seed major breakthroughs.
ARPA-H Program ISOs (topic-specific)
🇺🇸ARPA-H · United States
Funds United States health initiatives through topic-focused pathways across multiple mission areas and agencies.
Complement-ARIE — Open Funding (Seed)
🇺🇸NIH Common Fund · United States
Supports development of human-based new approach methodologies replacing animal models in relevant research.
ARPA-H Mission Office ISOs
🇺🇸ARPA-H · United States
Supports United States mission teams with boundary-pushing health initiatives beyond existing programme limits.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
🇺🇸NIH · United States
Funds two years of analytical validation then three of clinical validation for a cancer biomarker assay that already works on human samples.
ARPA-H SBIR/STTR
🇺🇸ARPA-H · United States
Funds United States small businesses bridging health and neuroscience technologies from feasibility into advanced development.